Retatrutide: The Next Generation Weight Loss Therapy Your Physician Should Know About
June 1, 2026 · Metabolic Regen Team
Key Takeaways
- ›Retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptors) — the first of its kind in clinical development
- ›Phase 2 trials showed average body weight reduction of up to 24.2% at 48 weeks — surpassing tirzepatide results
- ›Triple receptor action targets weight loss, metabolic health, and liver fat simultaneously
- ›Phase 3 trials are ongoing; compounded retatrutide is available through select physician-supervised programs
- ›An endocrinologist is the ideal physician to evaluate whether retatrutide fits your metabolic profile
If you’ve been following the evolution of GLP-1 medications — from semaglutide (Ozempic/Wegovy) to tirzepatide (Mounjaro/Zepbound) — you already know how dramatically this class of drugs has changed metabolic medicine. Now there’s a next step: retatrutide.
Retatrutide is not simply a more potent version of what came before. It’s a fundamentally different molecule that works on three separate hormone receptor systems simultaneously. Early clinical data suggests it may produce the most significant weight loss results ever seen from a pharmaceutical agent — and it’s already available through physician-supervised compounding programs.
Here’s what our physicians want you to know.
What Is Retatrutide?
Retatrutide (also called LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. While semaglutide targets only the GLP-1 receptor and tirzepatide targets GLP-1 and GIP receptors, retatrutide adds activation of the glucagon receptor — a third pathway that directly drives energy expenditure and liver fat reduction.
| Medication | Receptor Targets | Avg. Weight Loss | Status |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | FDA Approved |
| Tirzepatide | GLP-1 + GIP | ~22% | FDA Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | Up to 24.2% | Phase 3 / Compounded |
From our endocrinologist: “The glucagon component is what separates retatrutide from everything before it. Glucagon receptor activation increases resting energy expenditure — meaning your body burns more calories at rest — while also targeting liver fat directly. This makes it particularly compelling for patients with metabolic syndrome or NAFLD, not just those seeking weight loss.”
What the Clinical Data Shows
The pivotal Phase 2 trial published in The New England Journal of Medicine (2023) enrolled 338 adults with obesity. At 48 weeks:
- Patients on the highest dose (12 mg weekly) achieved a mean body weight reduction of 24.2%
- Over 80% of participants on the highest dose lost ≥15% of their body weight
- Over 25% of participants lost ≥30% of their body weight — a benchmark previously only seen with bariatric surgery
- Significant reductions in liver fat, waist circumference, blood pressure, and lipids were observed
- A1C improved in participants with type 2 diabetes
These are not incremental improvements. A 24% average weight reduction — with a quarter of patients achieving surgical-level results — represents a categorical shift in what’s possible with pharmacological intervention.
How Retatrutide Works: The Triple Mechanism
Understanding why retatrutide outperforms its predecessors requires a brief look at each receptor it targets:
GLP-1 Receptor (Glucagon-Like Peptide-1)
This is the same pathway activated by semaglutide and tirzepatide. GLP-1 receptor agonism suppresses appetite by slowing gastric emptying and signaling fullness to the brain. It also improves insulin secretion and reduces blood sugar levels.
GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide)
GIP receptor activation enhances insulin secretion, supports fat metabolism in adipose tissue, and helps balance the appetite-suppressing effects of GLP-1. Tirzepatide showed that adding GIP agonism to GLP-1 increased weight loss meaningfully over GLP-1 alone.
Glucagon Receptor
This is what makes retatrutide unique. Glucagon receptor activation increases energy expenditure (thermogenesis), drives liver fat breakdown, and amplifies overall metabolic rate. The glucagon pathway is why retatrutide shows particular promise for patients with fatty liver disease and those with high metabolic resistance to other agents.
Think of it this way: GLP-1 reduces what you eat. GIP improves how you process it. Glucagon increases how much your body burns. Retatrutide activates all three simultaneously.
Who May Benefit Most from Retatrutide?
Based on the clinical data and our clinical experience, retatrutide may be particularly appropriate for patients who:
- Haven’t achieved sufficient results on semaglutide or tirzepatide — a meaningful subset of patients are partial responders or non-responders to dual-agonist therapy
- Have non-alcoholic fatty liver disease (NAFLD/MASH) — the glucagon component drives hepatic fat reduction more aggressively than prior agents
- Have metabolic syndrome — multiple concurrent improvements in blood pressure, lipids, A1C, and weight make retatrutide a compelling single-agent option
- Are pursuing surgical-level weight loss without surgery — the proportion of patients achieving >25% body weight loss is unprecedented outside of bariatric surgery
- Have high baseline weight or BMI — higher absolute doses may be appropriate for patients with significant obesity
At Metabolic Regen MD, our physician evaluates your complete metabolic profile — including fasting labs, liver enzymes, A1C, lipid panel, and hormonal baseline — before recommending any GLP-1 class agent. Retatrutide is not right for every patient, but for the right metabolic profile, it may offer results not achievable with existing approved therapies.
Interested in whether retatrutide is right for you? Start your free physician consultation here.
Retatrutide Dosing: What to Expect
Retatrutide is administered as a once-weekly subcutaneous injection, following a dose-escalation schedule similar to semaglutide and tirzepatide. Gradual titration is essential to minimize gastrointestinal side effects during the adjustment period.
Typical dosing schedule (physician-directed, individualized):
- Starting dose: 2 mg weekly for 4 weeks
- Escalation: 4 mg, 8 mg, and up to 12 mg weekly based on tolerance and response
- Maintenance: individualized based on metabolic response and patient goals
Important: All dosing decisions at Metabolic Regen MD are made by our physician based on your specific labs, history, and response. We do not use one-size-fits-all protocols.
Side Effects and Safety Considerations
Retatrutide’s side effect profile is broadly consistent with the GLP-1 class, though the glucagon component introduces some considerations unique to this molecule:
Common (generally mild and transient):
- Nausea (most common, especially during dose escalation)
- Decreased appetite
- Vomiting or diarrhea
- Constipation
- Injection site reactions
Metabolic monitoring points:
- Blood glucose: Glucagon receptor activation can transiently raise blood sugar levels, particularly in diabetic patients. Close monitoring is essential, especially when transitioning from other antidiabetic agents.
- Heart rate: Modest increases in resting heart rate (similar to semaglutide) were observed in clinical trials.
- Liver enzymes: Hepatic fat reduction is rapid; liver enzyme monitoring during the first months is standard practice.
Contraindications (same as GLP-1 class):
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or active plans for pregnancy
- Pancreatitis history (relative contraindication; evaluate on a case-by-case basis)
Our physician reviews all contraindications, current medications, and your full medical history before prescribing. We do not prescribe through automated intake forms — every patient is personally evaluated.
Retatrutide vs. Semaglutide vs. Tirzepatide: How to Choose
The question we hear most from patients is: “Should I be on retatrutide instead of what I’m currently taking?”
The honest answer is that it depends on your specific situation. Here’s how our endocrinologist approaches the decision:
| If you… | Consider… |
|---|---|
| Are new to GLP-1 therapy with standard obesity | Semaglutide (established safety record, strong results) |
| Want maximum weight loss with insulin resistance | Tirzepatide (dual agonist, superior to semaglutide) |
| Haven’t hit your goal on tirzepatide | Retatrutide (triple agonist, adds glucagon pathway) |
| Have significant fatty liver disease | Retatrutide (glucagon component targets hepatic fat directly) |
| Prefer a needle-free option | Oral semaglutide (daily tablet, lower potency) |
Availability: Is Retatrutide Available Now?
Retatrutide is currently in Phase 3 clinical trials and has not yet received FDA approval for commercial sale. However, compounded retatrutide — prepared by PCAB-accredited compounding pharmacies under physician prescription — is legally available through licensed providers in the United States.
At Metabolic Regen MD, we work exclusively with licensed compounding pharmacies that meet the highest quality standards, including independent purity verification. All compounded retatrutide dispensed through our program is physician-prescribed, third-party tested, and shipped in temperature-controlled packaging.
If you’re ready to explore whether retatrutide is appropriate for your metabolic goals, our physician offers a free initial consultation — no commitment required.
Frequently Asked Questions
Is retatrutide safe?
Phase 2 trials showed a safety profile generally consistent with the GLP-1 class. The side effects were mostly gastrointestinal, dose-dependent, and resolved over time. However, because it is not yet FDA-approved, it is only appropriate for patients with a genuine medical indication and under close physician supervision with regular lab monitoring.
How soon will I see results with retatrutide?
Most patients begin to notice appetite changes within the first 2–4 weeks as the dose escalates. Meaningful weight loss — typically 5–10% of body weight — is usually observed within the first 2–3 months. Maximum results unfold over 6–12 months of sustained therapy.
Can I switch from semaglutide or tirzepatide to retatrutide?
Yes, in many cases. Our physician designs a transition protocol based on your current dose, response history, and metabolic labs. Most transitions begin with a washout period before initiating retatrutide at a starting dose.
How does retatrutide compare to bariatric surgery?
The Phase 2 data showed that approximately 26% of patients on retatrutide achieved ≥25% body weight loss — a range historically associated only with surgical intervention. For patients who are not surgical candidates or who prefer a non-surgical path, retatrutide may represent a clinically meaningful alternative. That said, surgery and pharmacotherapy are not directly comparable; a physician evaluation is essential.
Does insurance cover retatrutide?
Compounded retatrutide is not currently covered by insurance. Most of our patients pay out-of-pocket and many use HSA/FSA funds, which are eligible for physician consultations and compounded medications prescribed for a medical indication.
The Bottom Line
Retatrutide represents the most significant advance in weight loss pharmacology since tirzepatide — and by some measures, the most significant advance ever. For patients who haven’t achieved their goals on existing therapies, or who have complex metabolic profiles including fatty liver disease or high cardiovascular risk, it offers something genuinely new.
The most important factor is not which medication is the newest — it’s which medication is right for your metabolism, your history, and your goals. That question requires a physician who specializes in metabolic health, not a general practitioner or an automated online intake.
Our board-certified endocrinologist evaluates every patient personally. If retatrutide is appropriate for you, we’ll build a protocol around it. If another agent fits better, we’ll tell you honestly.
Start My Free Physician Consultation
Related reading: GLP-1 Weight Loss Programs at Metabolic Regen MD · How Our Telehealth Process Works
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved and is available only through compounding pharmacies under physician prescription. Always consult with a qualified physician before starting or changing any medical treatment. Individual results vary.
Ready to start?
Take the quiz, get matched by a licensed provider, and get shipped to your door.
Start now